12:00 AM
Nov 23, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

Cellceutix completed enrollment of >40 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle. Next half, the company...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >